Ugint Co Ltd Market Cap ($10.23 Million)

$10.23 Million USD  · ₩15.09 Billion KRW  · Rank #26871

Market Cap & Net Worth: Ugint Co Ltd (195990)

Ugint Co Ltd market cap. Ugint Co Ltd (KQ:195990) has a market capitalization of $10.23 Million (₩15.09 Billion) as of November 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #26871 globally and #2016 in its home market, demonstrating a -25.24% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ugint Co Ltd's stock price ₩927.00 by its total outstanding shares 16282297 (16.28 Million). Also see Ugint Co Ltd (195990) cash flow conversion for how efficiently the company converts equity into cash flow.

Ugint Co Ltd Market Cap History (2015–2026)

Ugint Co Ltd market cap history from 2015 to 2026. Data shows change from $20.60 Million to $10.23 Million (-8.28% CAGR). Check Ugint Co Ltd (195990) stock price for real-time trading data and today's change.

Index Memberships

Ugint Co Ltd is a constituent of 2 market indices:

Index Total Market Cap Weight (%) Rank by Market Cap
Kosdaq Composite Index
KOSDAQ
$203.83 Billion 0.01% #1105 of 1384
Kosdaq Composite Index
KQ11
$203.83 Billion 0.01% #1105 of 1384

Weight: Ugint Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Ugint Co Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Ugint Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 195990 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.

Latest Price to Sales (P/S) Ratio

0.00x

Ugint Co Ltd's market cap is 0.00 times its annual revenue

Industry average: 1.26x Lower than industry average

Latest Price to Earnings (P/E) Ratio

N/A

P/E ratio not applicable due to negative or zero earnings

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $27.31 Million $49.52 Billion $17.33 Million 0.00x 1.58x
2017 $12.85 Million $45.94 Billion -$11.63 Billion 0.00x N/A
2018 $8.64 Million $58.86 Billion -$11.06 Billion 0.00x N/A
2019 $8.87 Million $31.93 Billion -$35.69 Billion 0.00x N/A
2020 $20.25 Million $49.28 Billion -$58.97 Billion 0.00x N/A
2021 $10.65 Million $32.91 Billion -$10.03 Billion 0.00x N/A
2022 $4.66 Million $22.11 Billion -$8.14 Billion 0.00x N/A
2023 $6.01 Million $25.38 Billion -$25.74 Billion 0.00x N/A
2024 $4.97 Million $31.66 Billion -$15.63 Billion 0.00x N/A
2025 $2.87 Million $31.92 Billion -$48.92 Billion 0.00x N/A

Competitor Companies of 195990 by Market Capitalization

Companies near Ugint Co Ltd in the global market cap rankings as of November 5, 2026. Also see 195990 total asset value for a full breakdown of the balance sheet.

Key companies related to Ugint Co Ltd by market ranking:

  • GE Vernova LLC (NYSE:GEV): Ranked #79 globally with a market cap of $246.74 Billion USD.
  • Siemens Aktiengesellschaft (XETRA:SIE): Ranked #91 globally with a market cap of $218.11 Billion USD ( €186.56 Billion EUR).
  • SIEMENS AG SP. ADR 1/ 1/2 (F:SIEB): Ranked #121 globally with a market cap of $177.31 Billion USD ( €151.67 Billion EUR).
  • Schneider Electric S.E. (PA:SU): Ranked #148 globally with a market cap of $157.90 Billion USD ( €135.06 Billion EUR).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#79 GE Vernova LLC NYSE:GEV $246.74 Billion $918.20
#91 Siemens Aktiengesellschaft XETRA:SIE $218.11 Billion €269.75
#121 SIEMENS AG SP. ADR 1/ 1/2 F:SIEB $177.31 Billion €119.00
#148 Schneider Electric S.E. PA:SU $157.90 Billion €239.75

Market Capitalization of Ugint Co Ltd (2015–2026)

Market capitalization of Ugint Co Ltd from 2015 to today. Between 2015 and today, Ugint Co Ltd's market cap moved from $20.60 Million to $ 10.23 Million, with a yearly change of -8.28%.

Year Market Cap Change (%)
2026 ₩10.23 Million +256.54%
2025 ₩2.87 Million -42.22%
2024 ₩4.97 Million -17.43%
2023 ₩6.01 Million +29.15%
2022 ₩4.66 Million -56.27%
2021 ₩10.65 Million -47.41%
2020 ₩20.25 Million +128.23%
2019 ₩8.87 Million +2.68%
2018 ₩8.64 Million -32.79%
2017 ₩12.85 Million -52.93%
2016 ₩27.31 Million +32.59%
2015 ₩20.60 Million --

End of Day Market Cap According to Different Sources

On Nov 4th, 2026 the market cap of Ugint Co Ltd was reported to be:

Source Market Cap
Yahoo Finance $10.23 Million USD
MoneyControl $10.23 Million USD
MarketWatch $10.23 Million USD
marketcap.company $10.23 Million USD
Reuters $10.23 Million USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Ugint Co Ltd

KQ:195990 Korea Specialty Industrial Machinery
Market Cap
$10.23 Million
₩15.09 Billion KRW
Market Cap Rank
#26871 Global
#2016 in Korea
Share Price
₩927.00
Change (1 day)
-8.31%
52-Week Range
₩140.00 - ₩2415.00
All Time High
₩3950.00
About

RootK Co., Ltd. manufactures and sells machine tools and biotechnology products in South Korea and internationally. It offers tapping centers, spindle machines, machining and turning centers, and machining centers with long table. Additionally, It also offers bispecific antibody therapeutics for ophthalmic and oncology indications, including anti-VEGF/ANG2, anti-HER2/CD3, anti-GPC3/CD3, and anti-… Read more